Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22526

Shown on this page

Current sort

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

MD Anderson Cancer Center

Live official records

Open in full search

Conditions: End Stage Renal Disease (ESRD), Kidney Failure, Chronic Renal Disease, Hemodialysis
Interventions: InnAVasc Arteriovenous Graft (IG) surgical implant; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 22
States / cities: Phoenix, Arizona • La Mesa, California • Sarasota, Florida + 17 more

Conditions: Obesity or Overweight, Type 2 Diabetes Mellitus
Interventions: Placebo, Enicepatide; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 45
States / cities: Guntersville, Alabama • Tucson, Arizona • Irvine, California + 41 more

Conditions: Phelan-McDermid Syndrome
Interventions: NNZ-2591; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Glendale, California • San Diego, California + 9 more

Conditions: Sjögren´s Disease
Interventions: VAY736, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 23
States / cities: Peoria, Arizona • Searcy, Arkansas • Van Nuys, California + 20 more

Conditions: Cystic Fibrosis
Interventions: Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed; Other
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 3 Years to 18 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Non-small Cell Lung Cancer
Interventions: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 58
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 53 more

Conditions: Acute Lower Limb Arterial Occlusion
Interventions: Artix Thrombectomy System; Device
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 26
States / cities: San Francisco, California • New Haven, Connecticut • Washington D.C., District of Columbia + 22 more

Conditions: Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Bevacizumab; Drug · Biological
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 8
States / cities: Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 5 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Empasiprubart IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Rancho Mirage, California + 10 more

Conditions: Overweight or Obesity, CKD, Type 2 Diabetes
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 15 more

Conditions: Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Interventions: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more

Conditions: Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Interventions: Lopinavir / ritonavir; Drug
Lead sponsor: Daré Bioscience, Inc.; Industry
Eligibility: 22 Years to 50 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 8 more

Clinical trials in Houston, Texas

Filter and sort this location

Institutions in Houston

Live official records

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The ArtixASCEND Study

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)